Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Crinetics Pharmaceuticals ( (CRNX) ) is now available.
At the J.P. Morgan Healthcare Conference in January 2025, Crinetics Pharmaceuticals outlined its 2025 priorities, including increasing commercial readiness for the potential U.S. launch of paltusotine, pending FDA approval, and advancing clinical development of atumelnant. These efforts reflect Crinetics’ strategic focus on endocrine conditions, aiming to position the company as a leader in this niche market by enhancing patient access to innovative treatments.
More about Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for endocrine diseases. Their work includes investigational drugs like paltusotine and atumelnant, targeting conditions such as acromegaly, congenital adrenal hyperplasia, and Cushing’s disease.
YTD Price Performance: -24.38%
Average Trading Volume: 735,700
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.76B
See more data about CRNX stock on TipRanks’ Stock Analysis page.
